Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Viral Immunology
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1360843
This article is part of the Research Topic Changes in T cell populations and cytokine production in SARS-CoV-2 infected individuals; their role in prognosis View all 16 articles

Immune cell populations and induced immune responses at admission in patients hospitalized with vaccine breakthrough SARS-CoV-2 infections

Provisionally accepted
Adin Sejdic Adin Sejdic 1,2Hans J. Hartling Hans J. Hartling 3Jon G. Holler Jon G. Holler 1Lars Klingen Gjaerde Lars Klingen Gjaerde 4Birgitte Lindegaard Birgitte Lindegaard 1,2Arnold M. Dungu Arnold M. Dungu 1Filip Gnesin Filip Gnesin 5Maria Moeller Maria Moeller 3Rebecca S. Teglgaard Rebecca S. Teglgaard 3Carsten Niemann Carsten Niemann 2,4Patrick T. Brooks Patrick T. Brooks 3Charlotte S. Jørgensen Charlotte S. Jørgensen 6Kristina T. Franck Kristina T. Franck 6Thea K. Fischer Thea K. Fischer 2,7Hanne Vibeke H. Marquart Hanne Vibeke H. Marquart 2,3Zitta Barrella Harboe Zitta Barrella Harboe 1,2*Sisse R. Ostrowski Sisse R. Ostrowski 2,3
  • 1 Department of Pulmonary and Infectious Diseases, Copenhagen University Hospital, Hilleroed, Denmark
  • 2 University of Copenhagen, Copenhagen, Capital Region of Denmark, Denmark
  • 3 Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Capital Region of Denmark, Denmark
  • 4 Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Zealand, Denmark
  • 5 Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Capital Region of Denmark, Denmark
  • 6 Department of Virus and Microbiological Diagnostics, Statens Serum Institut, Copenhagen, Denmark
  • 7 Department of Clinical Research, Copenhagen University Hospital, Hillerød, Denmark

The final, formatted version of the article will be published soon.

    Vaccine breakthrough SARS-CoV-2 infections are common and of clinical and public health concern. However, little is known about the immunological characteristics of patients hospitalized due to these infections. We aimed to investigate and compare immune cell subpopulations and induced immune responses in vaccinated and non-vaccinated patients hospitalized with severe COVID-19.A nested case-control study on adults (> 18 years) who received at least two doses of a mRNA-COVID-19 vaccine and were hospitalized with SARS-CoV-2 breakthrough infections and severe COVID-19 between January 7, 2021, and February 1, 2022, were eligible for inclusion. Age-and sex-matched non-vaccinated controls were identified. Immunophenotyping was performed using a custom-designed 10-color flow cytometry prefabricated freeze-dried antibody panel (DuraClone, Beckman Coulter (BC), Brea, Calif). TruCulture (Myriad RBM, Austin, USA) was used to assess induced immune response in whole blood, revealing different critical signaling pathways as a proxy for immune function. All samples were obtained within 48 hours of admission.In total, 20 hospitalized patients with severe COVID-19 and a breakthrough SARS-CoV-2 infection were included, ten vaccinated and ten non-vaccinated patients. Vaccinated patients had lower concentrations of CD19 B cells (p = 0.035), naïve CD4 T cells (p = 0.015), a higher proportion of γδ1 T cells (p = 0.019), and higher unstimulated immune cell release of IL-10 (p = 0.015).We observed immunological differences between vaccinated and non-vaccinated patients hospitalized due to severe COVID-19 that indicate that vaccinated patients had lower B cell concentrations, lower concentrations of CD4 naïve T cells, a skewed gamma-delta V1/V2 ratio, and an exaggerated IL-10 response at admission. These results could indicate a suboptimal immune response involved in SARS-CoV-2 breakthrough infections that cause severe COVID-19 in vaccinated adults. However, the sample size was small, and further research is needed to confirm these results.

    Keywords: immune cell populations, Inflammation, vaccine breakthrough infection, mRNA vaccine against SARS-CoV2, Cytokines

    Received: 24 Dec 2023; Accepted: 17 May 2024.

    Copyright: © 2024 Sejdic, Hartling, Holler, Klingen Gjaerde, Lindegaard, Dungu, Gnesin, Moeller, Teglgaard, Niemann, Brooks, Jørgensen, Franck, Fischer, Marquart, Harboe and Ostrowski. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Zitta Barrella Harboe, Department of Pulmonary and Infectious Diseases, Copenhagen University Hospital, Hilleroed, 2100, Denmark

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.